Navigation Links
Otonomy Introduces Scientific Advisory Board
Date:3/30/2009

the ear for diagnostic purposes and the 3D anatomy of the inner ear. He was a clinical physiologist at the Institute for Sound and Vibrations Research, University of Southampton, England and did postdoctoral training at the National Institute for Environmental Health Sciences in North Carolina. Dr. Salt received his Ph.D. in cochlear physiology from the University of Birmingham, England, where he also earned his M.S. in neurocommunications. He was the winner of the 2008 Gold Medal Award from the Prosper Meniere Society and the 1999 Guyot Prize from the University of Groningen, The Netherlands, for "important work of great merits in the field of otological and biological research".

About Otonomy

Otonomy is an emerging biopharmaceutical company based in San Diego that is focused on the development and commercialization of novel treatments for diseases of the inner and middle ear. This field represents a large untapped opportunity with nearly 30 million Americans facing debilitating hearing and balance disorders. Currently, no approved drug treatments exist for these conditions. In addition, more than 5 million annual cases of ear infection are still treated with resistance-causing oral antibiotics or locally administered drugs that require surgical perforation of the ear drum. Otonomy is working in partnership with leading experts in the field to bring new drug therapies to these unserved patients. For more information, visit www.otonomy.com.

Editor's Note: Photographs available on request

    Media Contact
    Heidi Chokeir, Ph.D., or David Schull
    Russo Partners
    O (619) 528-2217
    M (858) 380-6584
    heidi.chokeir@russopartnersllc.com
    david.schull@russopartnersllc.com


'/>"/>
SOURCE Otonomy Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
2. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
3. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
4. Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting
5. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
6. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
7. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
8. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
9. Max Muscle Introduces First-Ever Probiotics Protein Bar
10. bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections
11. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to creating professional commercial video content, to analysis of athletic performance. Producing ... that go by too quickly to process with the naked eye. , ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is now accepting ... program. LOIs are due no later than Wednesday, October ... Discovery Grants are one-year, $50,000 grants that fund high risk/high ... or treatment paradigms for adults and children with brain ... earliest stages, in the hopes that it spurs additional ...
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ‘ Ebola ... not-so-distant future faced with an Ebola pandemic that is on the cusp of wiping ... enter the world of counterterrorism, and who continues to appear in this series of ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3
... ever involving patients with cutaneous T-cell lymphoma on schedule ... RADNOR, Pa., June 29 Yaupon Therapeutics, a privately ... enrollment for a pivotal Phase 2 clinical trial for ... (CTCL - stages 1-2a). The study, which is ...
... DOR BioPharma, Inc. ... late-stage biopharmaceutical company, announced today that investigators at the ... paper this morning in Bone Marrow Transplantation ... (oral beclomethasone dipropionate or BDP) decreases non-infectious inflammation of ...
... 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today reported that YM,s subsidiary, ... the issues between the companies in a cooperative ...
Cached Biology Technology:Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... -- Based on its recent analysis of the biometric products market, ... Company of the Year Award. DERMALOG is the leading German ... Africa . It has particularly gained prominence in ... of the largest biometric mass applications in the world, and ... of Nigeria with its biometric products. ...
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Fungi play key roles in nature and are valued for ... in several foods and pharmaceuticals produced on a large-scale basis for ... . While A. niger is an integral player in ... be deployed in breaking down plant cell walls to free up ...
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... (May 3, 2011) Cancer studies from Mercer University ... the American Association of Pharmaceutical Scientists, (AAPS) National Biotechnology ... -Wednesday, May 18 at the Hilton San Francisco Union ... for Cervical Cancer Cervical cancer is the ...
Cached Biology News:Same fungus, different strains 2Same fungus, different strains 3Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6AAPS national biotechnology conference to highlight breakthrough cancer treatments 2